Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults (Apr 01, 2024)
Live Webinar
Apr 01, 2024
1 AMA PRA Category 1 Credit™ ...Speakers
OVERVIEW
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults is organized by i3 Health and will be held on Apr 01, 2024.
Live Webinar: April 1, 2024
Statement of Need:
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated with substantial morbidity and reduced life expectancy. Outcomes for adults with chronic ASMD are affected by diagnostic delays that in turn delay monitoring and management of ASMD manifestations (Wasserstein et al, 2019). Furthermore, while treatment of ASMD has until now been solely supportive in nature, an acid sphingomyelinase (ASM) enzyme replacement therapy has recently been approved, presenting the first opportunity to address the pathology underlying this condition (US Food & Drug Administration, 2022). This live webinar, chaired by Dr. Neal Weinreb, Voluntary Associate Professor for Human Genetics at the University of Miami Miller School of Medicine, will provide expert perspectives on current challenges and new opportunities in the management of ASMD in adults.
Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess the clinical presentation and diagnostic workup of chronic ASMD in adults
• Evaluate the mechanism of action, efficacy, and safety of ASM enzyme replacement therapy for chronic ASMD in adults as elucidated by recent clinical trials
• Monitor and manage the multisystemic manifestations of ASMD
• Counsel patients on supportive services for patients with ASMD, including social services, genetic counseling, family counseling, and patient/caregiver support groups
KEY DATES
01 Apr, 2024
Event Start Date
01 Apr, 2024
Event End Date
ACCREDITATION & CREDITS
Accreditation:
Jointly Accredited Provider:
In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians:
i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.
Physician Assistants:
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category 1 credit for completing this program.
Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Nursing Continuing Professional Development:
A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.9 ANCC contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour.
SPEAKERS
TARGET AUDIENCE
PhysicianNursingPhysician AssistantNeurologistsGastroenterologistsHepatologistsNurse AssistantsPrimary Care PractitionersPrimary Care PhysiciansPulmonologistsNurse PractitionersPsychologistsPrimary Care ProvidersPractice NursesSPECIALITIES
NeurologistsNurse PractitionerNeurologyGeriatricsPrimary CarePrimary Care PhysiciansPhysician AssistantsMedical Genetics and GenomicsClinical GeneticsPulmonologistsHepatologyGastroenterologyGastroenterology NurseRELATED CONFERENCES & LIVE WEBINARS
By eMedEd, Inc.
Aug 30, 2023 - May 23, 2028 | Webcast
State required course for Alabama ...
1 AMA PRA Category 1 Credit™
...
...
1 AMA PRA Category 1 Credit™
...
...
Quick Links